Abstract
The human kinome describes a major group of intracellular signalling molecules. In the last few years, many molecules in the group have become targets for therapeutic interventions. Due to the conserved reaction mechanism of catalysis, protein kinases seem well “drugable” by small molecular weight inhibitors, thus opening the chance to novel oral bioavailable drug development. A large number of small molecule weight inhibitors for protein kinases have already been introduced into research and these molecules are extensively analysed in regard to their efficiency, potency and selectivity. Here we summarise the use of small molecule protein kinase inhibitors relevant for acute and chronic inflammation based on their essential role in cellular signaling mechanisms in immune cells such as macrophages, lymphoytes and granulocytes. We describe the progress made to develop inhibitors against Toll-like receptor associated kinases (IRAKs), against the MAPK kinase kinases Cot/Tpl-2 and TAK1, against Inhibitor-κB kinases (IKKs), against MAPK kinases (MEKs, MKKs), against MAPKs (ERK2, p38, JNKs) and against their downstream kinases MNK1 and MK2/3. This overview should help to keep up with the fast developing field and the continuously growing number of protein kinase inhibitors.
Keywords: Protein kinase, inflammation, innate immunity, cytokine, inhibitor
Current Medicinal Chemistry
Title: Protein Kinases as Small Molecule Inhibitor Targets in Inflammation
Volume: 14 Issue: 21
Author(s): M. Gaestel, A. Mengel, U. Bothe and K. Asadullah
Affiliation:
Keywords: Protein kinase, inflammation, innate immunity, cytokine, inhibitor
Abstract: The human kinome describes a major group of intracellular signalling molecules. In the last few years, many molecules in the group have become targets for therapeutic interventions. Due to the conserved reaction mechanism of catalysis, protein kinases seem well “drugable” by small molecular weight inhibitors, thus opening the chance to novel oral bioavailable drug development. A large number of small molecule weight inhibitors for protein kinases have already been introduced into research and these molecules are extensively analysed in regard to their efficiency, potency and selectivity. Here we summarise the use of small molecule protein kinase inhibitors relevant for acute and chronic inflammation based on their essential role in cellular signaling mechanisms in immune cells such as macrophages, lymphoytes and granulocytes. We describe the progress made to develop inhibitors against Toll-like receptor associated kinases (IRAKs), against the MAPK kinase kinases Cot/Tpl-2 and TAK1, against Inhibitor-κB kinases (IKKs), against MAPK kinases (MEKs, MKKs), against MAPKs (ERK2, p38, JNKs) and against their downstream kinases MNK1 and MK2/3. This overview should help to keep up with the fast developing field and the continuously growing number of protein kinase inhibitors.
Export Options
About this article
Cite this article as:
Gaestel M., Mengel A., Bothe U. and Asadullah K., Protein Kinases as Small Molecule Inhibitor Targets in Inflammation, Current Medicinal Chemistry 2007; 14 (21) . https://dx.doi.org/10.2174/092986707781696636
DOI https://dx.doi.org/10.2174/092986707781696636 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of FKBP5 in Mood Disorders: Action of FKBP5 on Steroid Hormone Receptors Leads to Questions About its Evolutionary Importance
CNS & Neurological Disorders - Drug Targets Dietary Phytochemicals in Chemoprevention of Cancer
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents microRNA, Cancer and Cancer Chemoprevention
Current Molecular Pharmacology Evaluation of a Reporter Gene Assay for Bioactivity Determination of Therapeutic Interferons through a Collaborative Study
Current Pharmaceutical Analysis RNA-Based Drugs: From RNA Interference to Short Interfering RNAs
Current Pharmaceutical Biotechnology Endothelial Dysfunction in Sepsis
Current Vascular Pharmacology The Forward Path for Biopharmaceuticals and Biosimilars: Emerging Options in the Selection of Host Cell Systems
Current Biotechnology Dual COX Inhibition and Upper Gastrointestinal Damage
Current Pharmaceutical Design Stem Cells and Cardiac Disease: Where are We Going?
Current Stem Cell Research & Therapy The Key Role of Akt Protein Kinase in Metabolic-Inflammatory Pathways Cross-Talk: TNF-α Down-Regulation and Improving of Insulin Resistance in HepG2 Cell Line
Current Molecular Medicine Quantitative Structure-Activity Relationships for Commercially Available Inhibitors of COX-2
Medicinal Chemistry Heat Shock Proteins (HSPs) Based Anti-Cancer Vaccines
Current Molecular Medicine Mapracorat, a Novel Non-Steroidal Selective Glucocorticoid Receptor Agonist for the Treatment of Allergic Conjunctivitis
Inflammation & Allergy - Drug Targets (Discontinued) Anti-Inflammatory Actions of the Heme Oxygenase-1 Pathway
Current Pharmaceutical Design Nitric Oxide-Dependent Neovascularization Role in the Lower Extremity Disease
Current Pharmaceutical Design Cytokine Release Syndrome in Pathogenesis and Treatment of COVID-19
Current Pharmaceutical Design Dual Modulators of Selected Plant Secondary Metabolites Targeting COVID-19 Main Protease and Interleukin-2: An <i>In-Silico</i> Approach based Novel Hypothesis
Coronaviruses Genetic Polymorphisms of Human Sulfate Transporters
Current Pharmacogenomics Delivery Systems for Applications in siRNA Technology
Drug Delivery Letters Pollen-Cross Allergenicity Mediated by Panallergens: A Clue to the Pathogenesis of Multiple Sensitizations
Inflammation & Allergy - Drug Targets (Discontinued)